Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Process D vs Process C PK study in resected melanoma
NCT03980314Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 1, randomised, double-blind trial of nivolumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Area under the concentration-time curve in one dosing interval at Week 17. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03980314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980314.